Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Saturday, Bristol Myers Squibb & Co (NYSE:BMY) released the first disclosure of data from the Phase 3 CheckMate -67T trial of the subcutaneous formulation of Opdivo (nivolumab) compared to intravenous (IV) Opdivo in advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy.
The subcutaneous Opdivo is co-formulated with Halozyme Therapeutics Inc’s (NASDAQ:HALO) recombinant human hyaluronidase.
Also Read: Bristol Myers, Exelixis Reveal 4-Year Followup Results From Cancer Treatment Study.
In the CheckMate -67T trial investigating subcutaneous nivolumab (n=248) vs. IV Opdivo (n=247):
The safety profile of subcutaneous nivolumab was consistent with the IV formulation.
Price Action: BMY shares closed at $49.70 on Friday.